CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-08-03. AI was used for research and drafting; the existence of all 1 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v1.0.
Verdict No. 2092 · Search date 2026-08-03 · Methodology v1.0

Ultra-processed food,
does it really help with Increased incidence of depressive symptoms?

30-Second Summary
C
Evidence Grade C · 54 · Safety caution
Higher ultra-processed food share tracked with incident depressive symptoms, but this was not a causal trial
This is a broad food category rather than a single toxic product. Persistent depressive symptoms or impaired functioning warrant professional assessment rather than relying on diet changes alone.
What the
research shows
The grade is C. In 26,730 NutriNet-Sante participants followed for a mean 5.4 years, 2,221 developed CES-D depressive symptoms. Each 10-point higher ultra-processed energy share was associated with HR 1.21 (95% CI 1.15 to 1.27); adjustment including baseline CES-D and antidepressant use gave 1.14 (1.09 to 1.20). This large prospective cohort did not randomize diet, and both exposure and outcome were self-reported.
What the
ads claim
NOVA defines processing level, not risk magnitude. The exposure included industrial breads, breakfast cereals, flavored dairy, sauces, snacks, and beverages.
*

Useful facts when choosing a product

  • This whole-diet percentage has no common serving size.
  • Sodium, sugar, saturated fat, fiber, and protein vary by product.
  • Verdict 877 is D with 24 points for omega-3 supplements preventing depression; this verdict concerns whole-diet NOVA share and incident CES-D symptoms.
ID

Chamgap Semantic Classification Code

Candidate index · review held

D.proportion-of-total-dietary-energy-classified.dietary.incidence-of-depressive-symptoms.increase.UNK

Dietary patterns and eating practices > proportion of total dietary energy classified > Dietary regimen > incidence of depressive symptoms > Increase claim > Unknown

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

Gap Measurement · Verdict 2092 · C 54
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Adjibade analyzed 20,380 women and 6,350 men after excluding baseline depressive symptoms and antidepressant users. Repeated 24-hour records estimated NOVA share, sex-specific CES-D thresholds identified incident symptoms over 5.4 years, and baseline CES-D was adjusted. No analysis excluding the first few years of events was confirmed. Public funding was verified; a prospectively registered primary outcome for this analysis was not.

02

Why this is classified as C (54)

A precise association in a large public prospective cohort is limited by self-reported exposure and outcome plus unregistered multiple exploration, giving C with 54 points.

Counterpoint. C means intermediate evidence for the association, not intermediate depression risk.

Rejudgment record. Cross-check applied — Assessed adjusted cohort hazard ratios, baseline-symptom sensitivity analysis, self-report, and unregistered exploratory limitations

Stored scoring profile
EndpointPSymptom or function itself is the target - including patient reports and performance tests
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

Stored derived and displayed grades match; this is not a current recalculation or validity check (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Higher ultra-processed food share and incident depressive symptomsCThe HR was precise, but the analysis was nonrandomized and self-reported.

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Adjibade M et al., 2019 NutriNet-SanteProspective cohort with repeated dietary records26,730 participants, mean 5.4 years, 2,221 incident casesFrench public health and research agenciesIncident CES-D depressive symptoms using sex-specific thresholdsHR 1.21 (1.15 to 1.27) per 10-point higher energy share; 1.14 (1.09 to 1.20) after baseline CES-D and antidepressant adjustmentLarge prospective cohort, but nonrandomized and self-reported
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-03).

Adjibade M, Julia C, Alles B, et al. Prospective association between ultra-processed food consumption and incident depressive symptoms in the French NutriNet-Sante cohort. BMC Med. 2019;17:78. PMID: 30982472. DOI: 10.1186/s12916-019-1312-y.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Evidence date: 2026-08-03 · Corrections: none

Cite this verdict

Ultra-processed food x incident depressive symptoms Evidence Grade C card
[Chamgap] Ultra-processed food x incident depressive symptoms — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/ultra-processed-food-incident-depressive-symptoms/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.